Novo-Backed Drugmaker Avalyn Raises $300 Million in Upsized IPO
Avalyn Pharma Inc., a biopharma company developing inhaled treatments for rare lung diseases, raised $300 million in a US initial public offering that priced at the top of its marketed range.
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.